Institut de Cancerologie de L'Ouest
Saint-Herblain, 44805, France
NCT Number: NCT04625621
Breast cancer is the leading female cancer in metropolitan France in terms of incidence and death. Among the therapeutic arsenal for the treatment of these cancers, surgery plays a very important role and even if a conservative treatment is possible in the majority of cases, there is still an indication for mastectomy in about 30% of cases.
Currently, only 30% of women who have undergone a mastectomy choose reconstruction.
The primary objective of breast reconstruction from a surgical point of view is to leave as few aesthetic and functional after-effects as possible while meeting the personal wishes of each woman according to her morphological, tissue and vascular characteristics.
There are currently 2 major surgical procedures for breast reconstruction: breast implant reconstructions and autologous reconstructions.
Breast reconstruction by prosthesis is the simplest and most widely used technique but, the controversies concerning implants with the PIP breast prostheses scandal in 2010 and more recently the anaplastic lymphoma scandal have tarnished the image of this type of reconstruction.
Alternatives to breast implants have been developed: autologous reconstructions using first pedicled tissue flaps, then free flaps, techniques that allow a more natural, more satisfactory aesthetic result with an evolution that follows the patient's own morphology but requiring specific training in microsurgery and not without postoperative complications.
Since 1999, the investigators have witnessed the evolution of another autologous technique, that of lipomodulin. Initially used to improve the results of reconstructions and the aesthetic sequelae of conservative treatments, it is now used as an exclusive reconstruction technique. Easily reproducible and offering several advantages, reconstruction by exclusive lipomodulin is increasingly appreciated by patients.
However, this increasingly practiced technique presents specific problems and this is what the investigators want to evaluate in this study.
The main objective of this study is to evaluate the practices within our establishment regarding breast reconstruction by exclusive lipomodulin in terms of feasibility. The secondary objectives are the evaluation of the cosmetic result and the quality of life of these patients after this type of reconstruction.
Looking for future studies?
Notify Me18 year and older
Female
Observational
Saint-Herblain, 44805, France
This is an observational, monocentric study using retrospective health data (2012-2020) combined with quality of life questionnaires.
The list of patients meeting the inclusion criteria will be collected using the Medical Information Department. Based on a screening of aggregate data from the center, the sample size is approximately 150 patients.
The questionnaires will be mailed to patients during a follow-up site visit:
The returned questionnaires will be analyzed. Other necessary data will be collected in the patients' computer files.
There is no provision for patient follow-up.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 18 months
Failure rate of the technique
Time frame: 18 months
Scale of evaluation of the aesthetic result by a third party (specific scale with 4 question/scale form 1 to 10).
Time frame: 6 months
BREAST-Q (Reported Outcome Assessment following Reconstructive Breast Surgery in 31 questions including 10 scale from 1 to 10)
Time frame: 6 months
World Health Organization Quality of Life - BREF (WHOQOL-BREF) is a self-report questionnaire which assesses 4 domains of quality of life (QOL): physical health, psychological health, social relationships, and environment. In addition, there are 2 items that measure overall QOL and general health.
Institut Cancerologie de l'Ouest
Other
Acronym: EXCLUFAT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06747065
Breast Cancer, Breast Diseases
Basel, Switzerland
View Trial DetailsNCT04233385
Arthralgia, Breast Cancer
Cleveland, Ohio, United States
View Trial DetailsNCT06415526
Breast Cancer, Breast Diseases
Taoyuan, Taiwan
View Trial DetailsNCT03764943
Breast Cancer, Breast Diseases
Madison, Wisconsin, United States
View Trial Details